RxDoctor Payments Data

Chris Wier

Family · Lexington, MONPI 1912245887

Payments from drug & device makers

$2,813in general payments, 2019–2025

Across 161 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$559
  • Lilly USA, LLC$469
  • Mylan Specialty L.p.$268
  • Amgen$212
  • AstraZeneca$210
  • Novo Nordisk$141
  • plus $954 from 17 others

What the payments were for

  • Food & beverage$2,813100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,813 in reported general payments places this provider in the 85th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$116,911
OzempicSemaglutide57$85,354
TrulicityDulaglutide33$70,833
EliquisApixaban53$57,567
MounjaroTirzepatide31$48,912
Tresiba Flextouch U-200Insulin Degludec25$33,135
RybelsusSemaglutide17$27,120
XareltoRivaroxaban12$20,494
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$9,542
Spiriva RespimatTiotropium Bromide15$8,758
MyrbetriqMirabegron11$8,343
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$7,977
Breo ElliptaFluticasone/Vilanterol21$7,884
Insulin Lispro Kwikpen U-100Insulin Lispro12$6,623
Levemir FlexpenInsulin Detemir22$6,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$117$133,645109 claims
Lilly USA, LLCTrulicity, Mounjaro$469$119,74564 claims
Novo NordiskOzempic, Rybelsus$141$112,47474 claims
PfizerEliquis$54$57,56753 claims
Johnson & JohnsonXarelto$32$20,49412 claims
Astellas Pharma US IncMyrbetriq$16$8,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,812 family providers in Missouri.

Other family in Lexington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →